中华灾害救援医学2024,Vol.11Issue(8) :925-927,941.DOI:10.13919/j.issn.2095-6274.ZHJY202405044

药物性肝损伤的临床新进展

Recent Clinical Advances in Drug-Induced Liver Injury

张秋月
中华灾害救援医学2024,Vol.11Issue(8) :925-927,941.DOI:10.13919/j.issn.2095-6274.ZHJY202405044

药物性肝损伤的临床新进展

Recent Clinical Advances in Drug-Induced Liver Injury

张秋月1
扫码查看

作者信息

  • 1. 214000 江苏无锡,无锡市第八人民医院消化内科
  • 折叠

摘要

药物性肝损伤(Drug Induced Liver Injury,DILI)是指由药物本身或其代谢物导致的肝脏损伤,在我国常由于中草药、膳食补充剂、美容塑形药物以及抗结核药物等引起,是临床引起急性肝衰竭的重要因素之一.本文主要对药物性肝损伤发病机制和生物标志物进行综述,以期提高临床用药安全性.

Abstract

Drug-induced liver injury(DILI)refers to liver damage caused by a drug or its metabolites.In Chi-na,it is often attributed to traditional Chinese herbal medicines,dietary supplements,cosmetic and slimming drugs,and anti-tuberculosis medications.DILI is also a significant clinical cause of acute liver failure.This paper provides a comprehensive review of the mechanisms and biomarkers of DILI,aiming to enhance the safety of clinical drug use.

关键词

药物性肝损伤/发病机制/生物标志物/安全性

Key words

drug-induced liver injury/pathogenesis/biomarkers/security

引用本文复制引用

出版年

2024
中华灾害救援医学

中华灾害救援医学

影响因子:0.796
ISSN:
段落导航相关论文